

to:

Howard Owens Art Unit 1623

fax #:

9,703-308-4556

re:

09/528,488

date:

March 4, 2003

pages:

11, including this cover sheet.

FAX RECEIVED

MAD

ir a onnis

GROUP 1600

The following is being resubmitted to the United States Patent and Trademark Office by Facsimile:

OFFICIAL

Entry is respectfullly requested.

[X] Amendment with Version to Show Changes Made (10 pages)

[X] Petition for three (3) month extension of time

[X] Certificate of Facsimile

CERTIFICATE OF FILING VIA FACSIMILE

The undersigned hereby certifies that the attached Amendment with Version to Show Changes Made with a petition for a three (3) month extension of time, was this day, March 04, 2003, filed in the United States Patent and Trademark Office via facsimile to facsimilie number 703-308-4556. Total Pages: 11

Gall E. Poulos

From the desk of...

Gail E. Poulos Patent Advisor USDA-ARS-OTT 5601 Sunnyside Ave. Room 4-1184 Beltsville, Maryland 20705-5131

> 301-504-5302 Fax: 301-504-5060

Please cancel claims 1-12 without prejudice or disclaimer.

Applicants reserve the right to file one or more continuation or divisional applications directed to the canceled subject matter.

Please add new claims 13-22 :

--13. (Newly added) A method for reducing apolipoprotein B production comprising

providing an apolipoprotein B reducing amount of a polymethoxyflavone selected from the group consisting of 5,6,7,8,4'-pentamethoxyflavone, 5,6,7,8,3',4'-hexamethoxyflavone, heptamethoxyflavone, sinensetin, tetra-O-methyl-scutellarein, 5-desmethylsinensetin and mixtures thereof.--

--14. (Newly added) A method for reducing apolipoprotein B production comprising

providing an apolipoprotein B reducing amount of a polymethoxyflavone selected from the group consisting of limocitrin-3,7,4'-trimethylether (5-hydroxy-3,7,8,3',4'-pentamethoxyflavone), limocitrin-3,5,7,4'-tetramethylether (5-hydroxy-3,7,8,3',4'-hexamethoxyflavone), limocitrin-3-5-7-4'-tetraethylether (8,3-dimethyoxy-3,5,7,4'-tetraethoxyflavone), limocitrin-3,7,4'-trimethylether-5-acetate, and mixtures thereof.--

--15. (Newly added) A method for reducing apolipoprotein B production comprising

providing an apolipoprotein B reducing amount of a polymethoxyflavone selected from the group consisting of 5-desmethylnobiletin (5-hydroxy-6,7,8,3',4'-pentamethoxyflavone), tetra-O-methylisoscutellarein (5,7,8,4'-tetramethoxyflavone),



sinensetin (5,6,7,3',4'-pentamethoxyflavone), 5
desmethylsinensetin (5-hydroxy-6,7,3',4'-tetramethoxyflavone),

quercetin tetramethylether (5-hydroxy-3,7,3',4'
tetramethoxyflavone), quercetin-3,5-dimethylether-7,3',4'
tribenzyl ether, nobiletin (5,6,7,8,3',4'-hexamethoxyflavone),

quercetin pentamethyl ether (3,5,7,3',4'-pentamethoxyflavone),

tangeretin (5,6,7,8,4'-pentamethoxyflavone), quercetin-5,7,3',4'
tetramethyl ether-3-acetate, 3,5,6,7,8,3',4'-heptamethoxyflavone,

5,7,3',4'-tetramethylether (3-hydroxy-5,7,3',4'
tetramethoxyflavone), and mixtures thereof.--

--16. (Newly added) A composition for reducing apolipoprotein B production comprising an apolipoprotein B reducing amount of a polymethoxyflavone selected from the group consisting of 5,6,7,8,4'-pentamethoxyflavone, 5,6,7,8,3',4'-hexamethoxyflavone, heptamethoxyflavone, sinensetin, tetra-O-methyl-scutellarein, 5-desmethylsinensetin and mixtures thereof.--

--17. (Newly added) A composition for reducing apolipoprotein B production comprising an apolipoprotein B reducing amount of a polymethoxyflavone selected from the group consisting of limocitrin-3,7,4'-trimethylether (5-hydroxy-3,7,8,3',4'-pentamethoxyflavone), limocitrin-3,5,7,4'-tetramethylether (5-hydroxy-3,7,8,3',4'-hexamethoxyflavone), limocitrin-3-5-7-4'-tetraethylether (8,3-dimethyoxy-3,5,7,4'-tetraethoxyflavone), limocitrin-3,7,4'-trimethylether-5-acetate, and mixtures thereof.--

--18. (Newly added) A composition for reducing apolipoprotein B production comprising an apolipoprotein B reducing amount of a

